"Development risk and attrition rates remain two of the greatest challenges to a successful biopharmaceutical program," said Philippe Stas, Head of Lonza’s Applied Protein Services group. "Our newly integrated preclinical services help mitigate both aspects by providing a window into the future of a biologic, which supports the successful selection and optimization as well as the early process development of promising drug candidates."

The Applied Protein Services platform complements Lonza’s well-established, industry-leading process development and manufacturing capabilities while advancing the company’s efforts to incorporate Quality by Design (QbD) principles.

Computer-based and cellular immunoprofiling for lead selection, lead comparison, optimization and surveillance

Technology platform for protein structure analysis, modeling, engineering, deimmunization and antibody optimization

Technology platform to resolve protein aggregation and stability challenges

For more information, please contact one of Lonza’s Applied Protein Services experts at appliedproteinservices@lonza.com